• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非小细胞肺癌切除术后的监测。

Surveillance of resected non-small cell lung cancer.

机构信息

Servicio Oncología Médica, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.

出版信息

Clin Transl Oncol. 2012 Oct;14(10):721-5. doi: 10.1007/s12094-012-0841-z. Epub 2012 Jul 21.

DOI:10.1007/s12094-012-0841-z
PMID:22855136
Abstract

Lung cancer is the most common cancer in the world. 15 % of all patients with lung cancer are diagnosed at an early stage, and surgery is the treatment of choice for them. 40 % of all patients survive more than 5 years after surgery, and most of them die as a result of systemic disease. Half of all recurrences are diagnosed within the first 24 months after curative treatment, and 90 % in the first 5 years. Despite this, it is not standardized who should do the monitoring, what additional tests are needed and how often should they be performed. We present here a review on the various recommendations in clinical guidelines.

摘要

肺癌是世界上最常见的癌症。15%的肺癌患者在早期被诊断出来,手术是他们的首选治疗方法。40%的患者在手术后 5 年以上仍能存活,其中大多数死于全身疾病。所有复发中有一半在根治性治疗后 24 个月内被诊断出来,90%在最初的 5 年内。尽管如此,谁来进行监测、需要哪些额外的检查以及应该多久进行一次检查,目前还没有标准化。我们在这里回顾了临床指南中的各种建议。

相似文献

1
Surveillance of resected non-small cell lung cancer.非小细胞肺癌切除术后的监测。
Clin Transl Oncol. 2012 Oct;14(10):721-5. doi: 10.1007/s12094-012-0841-z. Epub 2012 Jul 21.
2
Non-small cell lung cancer.非小细胞肺癌。
J Natl Compr Canc Netw. 2012 Oct 1;10(10):1236-71. doi: 10.6004/jnccn.2012.0130.
3
Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations.预测肺癌总生存期的替代标志物:ELCWP 建议。
Eur Respir J. 2012 Jan;39(1):9-28. doi: 10.1183/09031936.00190310. Epub 2011 Jul 7.
4
Follow-up of local (stage I and stage II) non-small-cell lung cancer after surgical resection.手术切除后局部(I期和II期)非小细胞肺癌的随访
Curr Treat Options Oncol. 2002 Feb;3(1):67-73. doi: 10.1007/s11864-002-0043-y.
5
[Recommendations for surgical treatment of nonsmall cell lung cancer].[非小细胞肺癌的外科治疗建议]
Pneumologia. 2009 Apr-Jun;58(2):135-40.
6
Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.第三届中国抗癌协会肿瘤临床化疗专业委员会非小细胞肺癌诊疗共识。
Ann Oncol. 2012 May;23(5):1223-1229. doi: 10.1093/annonc/mdr381. Epub 2011 Sep 22.
7
Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance.在常规计算机断层扫描监测下,早期肺癌幸存者的复发和第二原发性肺癌模式。
J Thorac Cardiovasc Surg. 2013 Jan;145(1):75-81; discussion 81-2. doi: 10.1016/j.jtcvs.2012.09.030. Epub 2012 Nov 3.
8
Prognostic factors for post-recurrence survival in patients with completely resected Stage I non-small-cell lung cancer.完全切除的Ⅰ期非小细胞肺癌患者复发后生存的预后因素
Eur J Cardiothorac Surg. 2014 Feb;45(2):262-7. doi: 10.1093/ejcts/ezt333. Epub 2013 Jun 27.
9
SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015.2015年SEOM非小细胞肺癌(NSCLC)治疗临床指南
Clin Transl Oncol. 2015 Dec;17(12):1020-9. doi: 10.1007/s12094-015-1455-z. Epub 2015 Dec 21.
10
Non-small cell lung cancer clinical practice guidelines in oncology.肿瘤学非小细胞肺癌临床实践指南
J Natl Compr Canc Netw. 2006 Jul;4(6):548-82. doi: 10.6004/jnccn.2006.0046.

引用本文的文献

1
Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer.血清中微小RNA-138及其靶mRNA PDK1对非小细胞肺癌患者的预后潜力
Med Oncol. 2014 Sep;31(9):129. doi: 10.1007/s12032-014-0129-y. Epub 2014 Jul 27.
2
Preoperative serum LMTK3 as a novel biomarker in non-small cell lung cancer.术前血清LMTK3作为非小细胞肺癌的一种新型生物标志物。
Tumour Biol. 2014 May;35(5):5007-11. doi: 10.1007/s13277-014-1660-3. Epub 2014 Feb 9.
3
Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer.

本文引用的文献

1
Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.SMRP、CA125 和 CYFRA 21-1 等生物标志物在曾接触石棉的工人队列中作为恶性间皮瘤和肺癌潜在肿瘤标志物的性能。
Arch Toxicol. 2011 Mar;85(3):185-92. doi: 10.1007/s00204-010-0580-2. Epub 2010 Aug 25.
2
Expression of Hsp27 and Hsp70 in lymphocytes and plasma in healthy workers and coal miners with lung cancer.热休克蛋白27(Hsp27)和热休克蛋白70(Hsp70)在健康工人及肺癌煤矿工人淋巴细胞和血浆中的表达
J Huazhong Univ Sci Technolog Med Sci. 2010 Aug;30(4):415-20. doi: 10.1007/s11596-010-0441-5. Epub 2010 Aug 17.
3
八精氨酸修饰的聚乙二醇化脂质体阿霉素:非小细胞肺癌的有效治疗策略。
Cancer Lett. 2013 Jul 10;335(1):191-200. doi: 10.1016/j.canlet.2013.02.020. Epub 2013 Feb 16.
Biological markers in lung cancer: A clinician's perspective.
肺癌的生物学标志物:临床医生的视角。
Cancer Biomark. 2010;6(3-4):123-35. doi: 10.3233/CBM-2009-0124.
4
Lung cancer biomarkers: FISHing in the sputum for risk assessment and early detection.肺癌生物标志物:从痰中寻找风险评估和早期检测的线索。
Cancer Prev Res (Phila). 2010 Apr;3(4):420-3. doi: 10.1158/1940-6207.CAPR-10-0052. Epub 2010 Mar 23.
5
The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence.荧光原位杂交技术检测痰液中的染色体非整倍体可预测肺癌的发生。
Cancer Prev Res (Phila). 2010 Apr;3(4):447-53. doi: 10.1158/1940-6207.CAPR-09-0165. Epub 2010 Mar 23.
6
Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.F18-氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描在非小细胞肺癌潜在根治性手术后患者中的临床价值:241例患者的经验
Interact Cardiovasc Thorac Surg. 2010 Jun;10(6):1009-14. doi: 10.1510/icvts.2009.227538. Epub 2010 Mar 2.
7
De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.表皮生长因子受体酪氨酸激酶抑制剂在 EGFR 突变阳性非小细胞肺癌患者中的新生耐药性。
J Thorac Oncol. 2010 Mar;5(3):399-400. doi: 10.1097/JTO.0b013e3181cee47e.
8
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials.适合二线化疗的晚期非小细胞肺癌患者的临床评估:来自九个随机试验个体数据的预后评分。
Eur J Cancer. 2010 Mar;46(4):735-43. doi: 10.1016/j.ejca.2009.12.013. Epub 2010 Jan 4.
9
Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer.非小细胞肺癌中表皮生长因子受体体细胞突变和基因拷贝数增加作为酪氨酸激酶抑制剂反应的预测生物标志物。
Clin Cancer Res. 2010 Jan 1;16(1):291-303. doi: 10.1158/1078-0432.CCR-09-1660. Epub 2009 Dec 22.
10
A follow-up of integrated positron emission tomography/computed tomography after curative resection of non-small-cell lung cancer in asymptomatic patients.根治性切除术后无症状非小细胞肺癌患者的正电子发射断层扫描/计算机断层扫描随访。
J Thorac Cardiovasc Surg. 2010 Jun;139(6):1447-51. doi: 10.1016/j.jtcvs.2009.09.055. Epub 2009 Dec 14.